Edgewise Therapeutics, Inc. (EWTX) stock analysis
In our weekly check, Edgewise Therapeutics, Inc. is graded D (A to F). Of 19 checks on debt, profit, cash flow and trend: 9 pass, warnings: 0, red flags: 10.
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as EWTX.
What our checks show for EWTX
Red flags
- Operating cash flow is negative while the company reports a profit: the profit does not arrive as cash.
- Weak EPS forecast
- Analysts expect the net margin to shrink by 395 points from today's 0%.
- The company has no revenue yet.
- Free cash flow is negative and the company has no revenue yet: it lives on its cash and new funding.
- The price swings a lot: 69% annual volatility. Expect large ups and downs.
- The stock has fallen as much as 85% from a peak. Would you have held through that?
- The share count grew by 61.5% in 2 years: each shareholder owns a smaller slice.
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Free cash flow is negative, so no cash is left over to cover pay in shares.
Strengths
- Debt is low: 0x equity.
- Earnings per share grew 94.4% a year over the last 3 years.
- The price is 5 times earnings (P/E), reasonable for its growth.
- Beta 0.28: the stock usually moves less than the market.
Similar companies
COGT · TVTX · IONS · DNTH · ADPT · SRRK
Questions
What grade does Edgewise Therapeutics, Inc. (EWTX) have?
In our weekly check, Edgewise Therapeutics, Inc. is graded D (A to F). Of 19 checks on debt, profit, cash flow and trend: 9 pass, warnings: 0, red flags: 10. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of EWTX stock?
This week's biggest flags for Edgewise Therapeutics, Inc.: Profits not backed by cash, Weak EPS forecast, Margins expected to shrink. In total 10 of 19 checks show a warning or a red flag.
What does Edgewise Therapeutics, Inc. do?
Edgewise Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as EWTX.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis